MX2022005999A - Composicion de medio para el cultivo de linfocitos t y metodo para el cultivo de linfocitos t mediante el uso de la misma. - Google Patents

Composicion de medio para el cultivo de linfocitos t y metodo para el cultivo de linfocitos t mediante el uso de la misma.

Info

Publication number
MX2022005999A
MX2022005999A MX2022005999A MX2022005999A MX2022005999A MX 2022005999 A MX2022005999 A MX 2022005999A MX 2022005999 A MX2022005999 A MX 2022005999A MX 2022005999 A MX2022005999 A MX 2022005999A MX 2022005999 A MX2022005999 A MX 2022005999A
Authority
MX
Mexico
Prior art keywords
cells
culturing
same
protein
activity
Prior art date
Application number
MX2022005999A
Other languages
English (en)
Inventor
Myoung Ho Jang
Chun-Pyo Hong
Young Joo Choi
June Sub Lee
Original Assignee
Gi Cell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gi Cell Inc filed Critical Gi Cell Inc
Publication of MX2022005999A publication Critical patent/MX2022005999A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Abstract

La presente invención se refiere a una composición para la proliferación de linfocitos T, que contiene un dímero de proteína de fusión que comprende una proteína IL-2 o una variante de esta y una proteína CD80 o un fragmento de esta, y a un método para cultivar los linfocitos T mediante el uso de la misma. Los linfocitos T cultivados de acuerdo con la presente invención aumentan la proliferación y la actividad de los linfocitos T incluso sin usar perlas magnéticas unidas a anticuerpos contra CD3/CD28, y proliferan los linfocitos T mediante el cultivo de células mononucleares de sangre periférica del propio paciente y no es probable que causen efectos secundarios en el cuerpo humano, y por lo tanto se usará ampliamente como un nuevo agente terapéutico de linfocitos T. Además, en el caso de los linfocitos T CD8+ cultivados como se describió anteriormente, la actividad de estos aumenta y, por tanto, los linfocitos T CD8+ pueden usarse como un agente terapéutico más efectivo.
MX2022005999A 2019-11-20 2020-11-19 Composicion de medio para el cultivo de linfocitos t y metodo para el cultivo de linfocitos t mediante el uso de la misma. MX2022005999A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190149779 2019-11-20
PCT/KR2020/016379 WO2021101271A1 (ko) 2019-11-20 2020-11-19 T 세포 배양용 배지 조성물 및 이를 이용한 t 세포의 배양 방법

Publications (1)

Publication Number Publication Date
MX2022005999A true MX2022005999A (es) 2022-06-17

Family

ID=75981075

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005999A MX2022005999A (es) 2019-11-20 2020-11-19 Composicion de medio para el cultivo de linfocitos t y metodo para el cultivo de linfocitos t mediante el uso de la misma.

Country Status (12)

Country Link
US (1) US20230015408A1 (es)
EP (1) EP4063492A4 (es)
JP (1) JP2023503098A (es)
KR (1) KR20210061956A (es)
CN (1) CN114829585A (es)
AU (1) AU2020389422A1 (es)
BR (1) BR112022009521A2 (es)
CA (1) CA3157613A1 (es)
IL (1) IL292934A (es)
MX (1) MX2022005999A (es)
TW (1) TWI812900B (es)
WO (1) WO2021101271A1 (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000334A1 (fr) * 1984-06-20 1986-01-16 Takeda Chemical Industries, Ltd. Nouveau transformant et son utilisation
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
JP2010501173A (ja) * 2006-08-23 2010-01-21 バイネックス カンパニー リミテッド 免疫治療用活性化リンパ球の製造方法
NZ591130A (en) * 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
KR102062407B1 (ko) 2010-12-09 2020-01-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
PE20140303A1 (es) 2011-02-10 2014-03-22 Roche Glycart Ag Polipeptidos interleuquina-2 mutantes
EP3357511B1 (en) * 2011-06-30 2020-05-13 Genzyme Corporation Inhibitors of t-cell activation
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CN103667189B (zh) * 2013-09-24 2015-10-28 上海宇研生物技术有限公司 用于治疗肺癌的cd8毒性t淋巴细胞及其制备方法
MA45488A (fr) * 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
TW201722985A (zh) * 2015-11-02 2017-07-01 戊瑞治療有限公司 Cd80胞外域多肽及其用於癌症治療
SI3436079T1 (sl) * 2016-04-01 2022-01-31 Kite Pharma, Inc. Himerni antigen in T celični receptorji ter način uporabe
CA3019577A1 (en) * 2016-04-01 2017-10-05 Vycellix Inc Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
CA3040823A1 (en) * 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
CN107857819A (zh) * 2017-07-03 2018-03-30 江苏西迪尔生物技术有限公司 多功能融合蛋白及其应用
CN110204619B (zh) * 2019-06-11 2020-06-05 南京融捷康生物科技有限公司 包含FcγRⅠ的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
TWI812900B (zh) 2023-08-21
CN114829585A (zh) 2022-07-29
WO2021101271A1 (ko) 2021-05-27
KR20210061956A (ko) 2021-05-28
US20230015408A1 (en) 2023-01-19
EP4063492A4 (en) 2024-01-17
JP2023503098A (ja) 2023-01-26
TW202134428A (zh) 2021-09-16
BR112022009521A2 (pt) 2022-08-16
IL292934A (en) 2022-07-01
EP4063492A1 (en) 2022-09-28
CA3157613A1 (en) 2021-05-27
AU2020389422A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
Putnam et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation
Cheng et al. Natural killer cell lines in tumor immunotherapy
Hsu et al. Prostaglandin E2 potentiates mesenchymal stem cell–induced IL-10+ IFN-γ+ CD4+ regulatory T cells to control transplant arteriosclerosis
Lim et al. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo
Gao et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells
Hof-Nahor et al. Human mesenchymal stem cells shift CD8+ T cells towards a suppressive phenotype by inducing tolerogenic monocytes
Min et al. Optimization of large-scale expansion and cryopreservation of human natural killer cells for anti-tumor therapy
Khan et al. Expanded human blood-derived γδT cells display potent antigen-presentation functions
EP3344759A1 (en) Method for natural killer cell expansion
McCurdy et al. Immune reconstitution after T-cell replete HLA-haploidentical transplantation
Moustaki et al. Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function
TWI612137B (zh) 含免疫細胞之組成物的製造方法及癌症治療用組成物
CN102428173A (zh) Nk细胞的扩增
US20200199532A1 (en) Compositions and methods for expanding ex vivo natural killer cells and therapeutic uses thereof
Torelli et al. A good manufacturing practice method to ex vivo expand natural killer cells for clinical use
KR20160063114A (ko) T 세포를 이용한 자연살해세포의 배양방법
DE69635924D1 (de) Isolierung und züchtung von schwannzellen
Künkele et al. Manufacture of chimeric antigen receptor T cells from mobilized cyropreserved peripheral blood stem cell units depends on monocyte depletion
Peragine et al. Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients
Oyer et al. Cryopreserved PM21-particle-expanded natural killer cells maintain cytotoxicity and effector functions in vitro and in vivo
Ou et al. Novel biomanufacturing platform for large-scale and high-quality human T cells production
Malone et al. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer
Bagheri et al. Current progress in cancer immunotherapy based on natural killer cells
Maldonado-Perez et al. Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma
CN105838674A (zh) 一种免疫抑制剂诱导调节性cd8+t细胞体外扩增的方法